Assessing the Evolving Role of Anti-TNF Biosimilars in Inflammatory Bowel Disease: Rationale and Considerations for Management

Tuesday, December 6, 2022

6:30 AM – 7:30 AM

Location: Northern Hemisphere D

Chair(s)

Aline Charabaty, MD

Assistant Clinical Director of the GI Division
Johns Hopkins School of Medicine
Potomac, Maryland

Parambir S. Dulai, MD

Associate Professor of Medicine, Director of GI Clinical Trials and Precision Medicine
Northwestern University
Chicago, Illinois
Shubha Bhat, PharmD, MS, BCACP

Clinical Pharmacy Specialist - Gastroenterology
Cleveland Clinic

Disclosure(s):

Aline Charabaty, MD: disclosed no relevant financial relationship with any ineligible company (commercial interest).

This session is supported by a joint educational grant from Organon and Fresenius Kabi USA, LLC.

Define and discuss the regulatory review and approval process that ensures the efficacy and safety of biosimilars
Evaluate the most recent safety, efficacy, and switching data associated with biosimilars for the management of IBD
Develop strategies to incorporate biosimilars into clinical practice, including patient education and personalized treatment plans for IBD management